Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Dyax Corp. (DYAX) Appoints Dr. Burd Adelman As Chief Medical Officer

|Includes: Dyax Corp. (DYAX)

Today, Dyax Corp. announced that it has appointed Burt Adelman, M.D., to the position of Chief Medical Officer. As Dyax's new CMO, Dr. Adelman will lead the development and regulatory strategy for the company's non-histamine-mediated angioedema franchise.

"Burt is a thought leader with an unparalleled record of success in developing and commercializing important therapeutics," remarked Gustav Christensen, President and Chief Executive Officer of Dyax. "His scientific, clinical, regulatory and market-based expertise will be invaluable as we expand our KALBITOR-led angioedema franchise. We look forward to his contributions toward optimizing KALBITOR in hereditary angioedema, advancing KALBITOR in ACE inhibitor-induced angioedema, developing the first-ever laboratory test for non-histamine-mediated angioedemas, and progressing Dyax's next-generation plasma kallikrein inhibitor toward the clinic."

Dr. Adelman is experienced in drug development and commercialization, having led the successful development of a number of important biologic and small molecule therapeutics, including Angiomax®, Avonex®, Amevive®, and Tysabri®. His professional career began in 1991 with Biogen as Director of Medical Research, and held positions of increasing responsibility including Vice President, Regulatory Affairs, Vice President, Development Operations, and Executive Vice President, Research and Development.

Dr. Adelman retired from Biogen Idec as Executive Vice President of Portfolio Strategy in 2007. He currently serves as a lecturer in medicine at the Harvard Medical School. He was Associate Professor of Medicine at the Medical College of Virginia and Chief of the Hematology-Oncology service at the Hunter Holmes McGuire VA Medical Center.

"Dyax has established KALBITOR as a leader in the acute hereditary angioedema treatment space, and with this, there exists a tremendous opportunity to further expand the Company's angioedema platform," stated Dr. Adelman, "I am excited to be working with the Dyax team, as we focus on developing a suite of products designed to identify and appropriately treat the tens of thousands of patients affected by non-histamine-mediated angioedemas."

For more information, visit the company's website at dyax.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net